CT-996

• Description :

  CT-996 is an orally active GLP-1RA agonist, with an EC50 of 0.49 nM. CT-996 reduces the β-arrestin recruitment and GLP-1R internalization. CT-996 suppresses postprandial blood glucose following a mixed meal tolerance test (MMTT) in mice expressing the human GLP-1 receptor and enhances glucose stimulated insulin secretion (GSIS) during an intravenous glucose challenge in obese monkeys. CT-996 can be used for the study of type 2 diabetes (T2D) and obesity[1][2].

• Product Name Alternative :

  RO7795081; RG6652

• UNSPSC :

  12352100

• Target :

  Arrestin; GLP Receptor

• Related Pathways :

  GPCR/G Protein

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Purity :

  99.97

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  C[C@@H](C[C@H](CC1)OC2=NC(COC3=C(C=C(C=C3)F)F)=NC=C2)N1CC(N(C4=C5)C[C@@H]6CCO6)=NC4=CC=C5C(O)=O

• Molecular Formula :

  C30H31F2N5O5

• Molecular Weight :

  579.59

• References & Citations :

  [1]Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Aug;24 (8) :631-650. |[2]JIAN LUO, et al. Efficacy of CT-996, an Oral Small Molecule GLP-1 Receptor Agonist, in Human GLP-1 Receptor Knockin Mice and Obese Cynomolgus Monkeys. Diabetes 14 June 2024; 73 (Supplement_1) : 771–P.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2810808-95-6]